H. Park

Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.

R. Cáliz Cáliz, P. Díaz del Campo Fontecha, J. M. Aguado García, 2023, Reumatologia clinica.

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

C. Díaz-Torné, P. Riera, A. M. Millán, 2023, Arthritis Research & Therapy.

Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?

Silvia Vidal, Héctor Corominas, H. Park, 2024, Journal of clinical medicine.

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis

Silvia Vidal, Héctor Corominas, H. Park, 2024, Medicina.

Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study

C. Díaz-Torné, Silvia Vidal, H. Park, 2024, Scientific reports.